Department of Neuroinflammation, Institute of Neurology, University College London, London, United Kingdom.
PLoS One. 2012;7(2):e30708. doi: 10.1371/journal.pone.0030708. Epub 2012 Feb 16.
Mesenchymal stem cells have been demonstrated to ameliorate experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis, prompting clinical trials in multiple sclerosis which are currently ongoing. An important question is whether this therapeutic effect generalises to other autoimmune neurological diseases. We performed two trials of efficacy of MSCs in experimental autoimmune neuritis (EAN) in Lewis (LEW/Han (M)Hsd) rats, a model of human autoimmune inflammatory neuropathies. No differences between the groups were found in clinical, histological or electrophysiological outcome measures. This was despite the ability of mesenchymal stem cells to inhibit proliferation of CD4+ T-cells in vitro. Therefore the efficacy of MSCs observed in autoimmune CNS demyelination models do not necessarily generalise to the treatment of other forms of neurological autoimmunity.
间充质干细胞已被证明可以改善实验性自身免疫性脑脊髓炎（EAE），这是多发性硬化症的一种模型，促使目前正在进行多发性硬化症的临床试验。一个重要的问题是，这种治疗效果是否普遍适用于其他自身免疫性神经疾病。我们在 Lewis（LEW/Han（M）Hsd）大鼠的实验性自身免疫性神经炎（EAN）中进行了两次间充质干细胞疗效试验，这是一种人类自身免疫性炎症性神经病的模型。在临床、组织学或电生理学结果测量方面，两组之间没有发现差异。尽管间充质干细胞能够抑制体外 CD4+T 细胞的增殖。因此，在自身免疫性中枢神经系统脱髓鞘模型中观察到的间充质干细胞的疗效不一定普遍适用于治疗其他形式的神经自身免疫。
